Anti-Inflammatory Activities of Leaf Oil from Cinnamomum subavenium In Vitro and In Vivo .

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Hindawi Pub. Co.
    • Subject Terms:
      Anti-Inflammatory Agents/*pharmacology ; Cinnamomum/*chemistry ; Plant Leaves/*chemistry ; Plant Oils/*pharmacology; Animals ; Anti-Inflammatory Agents/chemistry ; Cyclooxygenase 2/immunology ; Cytokines/immunology ; Inflammation/chemically induced ; Inflammation/drug therapy ; Inflammation/immunology ; Lipopolysaccharides/toxicity ; Mice ; NF-kappa B/immunology ; Nitric Oxide/immunology ; Nitric Oxide Synthase Type II/immunology ; Plant Oils/chemistry ; RAW 264.7 Cells
    • Abstract:
      The study determined the chemical constituents and anti-inflammatory effects of leaf oil from Cinnamomum subavenium (CS-LO) that has been used in folk medicine to treat various symptoms including inflammation. The anti-inflammatory effects of the oil were evaluated by LPS-stimulated RAW264.7 cells and the Carr-induced hind mouse paw edema model, respectively. In vitro , nitric oxide (NO), prostaglandin E2 (PGE 2 ), TNF- α , IL-6, and IL-1 β were significantly decreased by CS-LO, and the expression of nuclear factor- κ B (NF- κ B) protein was blocked as well. In in vivo, the malondialdehyde (MDA) and paw edema levels were decreased by CS-LO, and the same result came up on the NO and tumor necrosis factor (TNF-a) of serum at the 5th h after Carr injection. In addition, iNOS and COX-2 immunoreactive cells of the paw tissue were decreased significantly by CS-LO (200 mg/kg) in histological examination. The present findings indicated that CS-LO have anti-inflammatory properties, and the effects might be caused through inhibiting iNOS, COX-2, TNF- α , IL-1 β , and IL-6 expression via affecting NF- κ B pathway, which will provide a power scientific basis for CS-LO to be used as the treatment of inflammatory diseases.
    • References:
      J Biochem Mol Biol. 2002 Nov 30;35(6):537-46. (PMID: 12470586)
      J Nat Prod. 2007 Jan;70(1):103-6. (PMID: 17253858)
      Bioresour Technol. 2008 Jun;99(9):3908-13. (PMID: 17826984)
      Mol Immunol. 2008 Feb;45(4):887-97. (PMID: 17875325)
      Chem Pharm Bull (Tokyo). 2008 Jan;56(1):97-101. (PMID: 18175985)
      Bioresour Technol. 2008 Dec;99(18):8783-7. (PMID: 18513962)
      Int J Biochem Cell Biol. 2008;40(11):2572-82. (PMID: 18571461)
      Nat Prod Res. 2008;22(12):1055-9. (PMID: 18780246)
      Br J Nutr. 2009 May;101 Suppl 1:S1-45. (PMID: 19586558)
      Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034. (PMID: 20066092)
      Nat Prod Res. 2010 Mar;24(5):423-7. (PMID: 20306364)
      J Agric Food Chem. 2010 Jun 23;58(12):7445-52. (PMID: 20507140)
      Food Chem Toxicol. 2010 Oct;48(10):2913-9. (PMID: 20655974)
      J Ethnopharmacol. 2011 Jan 27;133(2):743-50. (PMID: 21073940)
      Integr Cancer Ther. 2011 Dec;10(4):350-8. (PMID: 21196431)
      J Ethnopharmacol. 2011 May 17;135(2):545-52. (PMID: 21466841)
      Evid Based Complement Alternat Med. 2011;2011:895857. (PMID: 21584194)
      J Agric Food Chem. 2011 Aug 10;59(15):8187-92. (PMID: 21707085)
      J Ethnopharmacol. 2011 Sep 1;137(1):503-11. (PMID: 21708241)
      J Agric Food Chem. 2011 Oct 26;59(20):11211-8. (PMID: 21830830)
      PLoS One. 2012;7(5):e35922. (PMID: 22590514)
      Food Chem Toxicol. 2012 Sep;50(9):3336-42. (PMID: 22735499)
      Food Chem Toxicol. 2013 Jul;57:126-31. (PMID: 23541436)
      Mol Immunol. 2017 Mar;83:46-51. (PMID: 28095349)
      Inflammation. 2018 Jun;41(3):835-845. (PMID: 29508185)
      Biochimie. 1995;77(3):147-61. (PMID: 7647106)
      Eur Cytokine Netw. 1996 Apr-Jun;7(2):93-124. (PMID: 8688493)
      Br J Pharmacol. 1998 Mar;123(6):1119-26. (PMID: 9559895)
    • Accession Number:
      0 (Anti-Inflammatory Agents)
      0 (Cytokines)
      0 (Lipopolysaccharides)
      0 (NF-kappa B)
      0 (Plant Oils)
      31C4KY9ESH (Nitric Oxide)
      EC 1.14.13.39 (Nitric Oxide Synthase Type II)
      EC 1.14.13.39 (Nos2 protein, mouse)
      EC 1.14.99.- (Ptgs2 protein, mouse)
      EC 1.14.99.1 (Cyclooxygenase 2)
    • Publication Date:
      Date Created: 20190328 Date Completed: 20190718 Latest Revision: 20200225
    • Publication Date:
      20240105
    • Accession Number:
      PMC6402240
    • Accession Number:
      10.1155/2019/1823149
    • Accession Number:
      30915347